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Low-level light treatment 
ameliorates immune 
thrombocytopenia
Jingke Yang1,†, Qi Zhang1, Peiyu Li1, Tingting Dong1 & Mei X. Wu1,2
Immune thrombocytopenia (ITP) is an immune-mediated acquired bleeding disorder characterized 
by abnormally low platelet counts. We reported here the ability of low-level light treatment (LLLT) 
to alleviate ITP in mice. The treatment is based on noninvasive whole body illumination 30 min a day 
for a few consecutive days by near infrared light (830 nm) transmitted by an array of light-emitting 
diodes (LEDs). LLLT significantly lifted the nadir of platelet counts and restored tail bleeding time when 
applied to two passive ITP models induced by anti-CD41 antibody. The anti-platelet antibody hindered 
megakaryocyte differentiation from the progenitors, impaired proplatelet and platelet formation, 
and induced apoptosis of platelets. These adverse effects of anti-CD41 antibody were all mitigated 
by LLLT to varying degrees, owing to its ability to enhance mitochondrial biogenesis and activity in 
megakaryocytes and preserve mitochondrial functions in platelets in the presence of the antibody. The 
observations argue not only for contribution of mitochondrial stress to the pathology of ITP, but also 
clinical potentials of LLLT as a safe, simple, and cost-effective modality of ITP.
Immune thrombocytopenia (ITP) is an autoimmune hemorrhagic disorder, characterized by a transient or per-
sistent decline of circulating platelets and the absence of other conditions known to induce thrombocytopenia. Its 
overall incidence is between 1.9 and 6.4 per 105 children and 3.3 per 105 adults annually1. Signs and symptoms of 
ITP vary widely with patients. Most of them have either no symptoms or minimal bruising, whereas others may 
experience serious bleeding, including extensive skin, mucosal, gastrointestinal or intracranial hemorrhage2. ITP 
patients are primarily treated by corticosteroids as a first-line therapy with response rates of 70–90%. However, 
long-term use of corticosteroids is not recommended due to side effects such as gastrointestinal distress and 
osteoporosis2,3. The majority of patients treated with corticosteroid relapses during drug tapering or after with-
drawal, and thus requires further therapy2. One of the standard second-line therapies is splenectomy, which offers 
approximately 60% long-term stable response rate but with an increased risk for postoperative complications4,5. 
In recent years, antibody against B cells named rituximab and thrombopoietin (TPO) receptor agonists like 
eltrombopag and romiplostim serve as second-line options with good tolerance and promising response rates6,7. 
Spleen tyrosine kinase inhibitors such as fostamatinib that is in phase III clinical trials might also offer another 
therapy for ITP. However, rituximab sometimes increased susceptibility to infections and neutropenia8,9. Clinical 
study showed that long-term treatment with eltrombopag or romiplostim could trigger some adverse effects, 
including liver enzyme elevation, thrombolic events and increased bone marrow reticulin6,7. Furthermore, these 
second-line drugs are all very expensive. We aimed at development of a simple, safe, and cost-effective alternative 
to manage ITP.
Low-level light refers to red to near infrared lasers with a wavelength of 600–1,100 nm, an output power 
of 1–500 mW, and relatively low energy densities (0.04–50 J/cm2), in either a continuous wave or pulsed 
mode. It has been used in the clinics for decades in wound healing, tissue repair, pain relief, and inflamma-
tion reduction with a long safety record10–13. Mitochondrial cytochrome c oxidase is currently thought to be 
one of the major photoacceptors for the initial effects of low-level light14. Several investigators, including 
us, have shown that low-level light treatment (LLLT) modulates ATP production, reactive oxygen species 
(ROS) formation, apoptosis, cellular metabolic process, and signaling transduction pathways secondarily 
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to more sufficient function of mitochondria under various conditions of stress15–17. Recently, we discovered 
that 810-nm continuous wave diode laser at 30 J/cm2 could penetrate into mouse bone marrow noninvasively 
without incurring any significant heat18. Noninvasive whole body illuminations with the LLLT cured acute 
thrombocytopenia induced by irradiation, chemotherapeutic drug, or anti-CD41 antibody much faster than 
sham-light treatment18. We found that LLLT bolstered mitochondrial biogenesis predominantly in polyploid 
megakaryocytes (MKs), increasing platelet production both in vivo and in vitro18. In the current study, we 
apply an array of light-emitting diodes (LEDs), instead of diode laser, to two passive ITP mouse models to 
gain similar results. In comparison with diode laser, LED is safer and more convenient and cost-effective. 
Moreover, an LED array can illuminate a relative large area of the body in a hands-free manner, in sharp 
contrast to a point-by-point application of a laser system19. LED illumination appears as effectively as a diode 
laser in ITP amelioration.
Results
LLLT ameliorates ITP. To investigate thrombopoietic effects of LLLT, we used a passive ITP mouse model 
by daily injecting anti-CD41 antibody at 0.1 mg/kg body weight. The mice were then treated with either sham 
light or 830-nm LED at 36 J/cm2 in 4 hours after anti-CD41 antibody injection and the similar LLLT continued 
once a day up to 5 days. Platelet counts were enumerated daily before each antibody injection. As shown in 
Fig. 1a, a single dose of anti-CD41 antibody diminished platelet counts by 40% in ITP+sham group compared 
with the control group. LLLT lifted the nadir effectively by only two treatments (P < 0.01) in ITP+LLLT group 
when compared to ITP+sham group. Continuous LLLT daily greatly prevented a loss of platelets and sustained 
platelet counts above 60% of the control, whereas the mice remained severely thrombocytopenic in ITP+sham 
Figure 1. LLLT ameliorates ITP. Mice were administered with anti-CD41 antibody (ITP) at either 0.1 mg/kg 
daily (a,b) or twice, one on day 0 and the other on day 3 each at 0.5 mg/kg (c,d). Control mice received PBS only. 
Noninvasive whole body LLLT at 36 J/cm2 was administered daily at 4 hr after each antibody injection from day 
0 to day 4. Platelet counts (a,c) were enumerated before each antibody injection. Tail bleeding time (b,d) was 
assessed on day 2 (b) or 4 (d) after the first antibody injection. All data represent mean ± SEM; n = 12; ns, no 
significance; and *P < 0.05, **P < 0.01, ***P < 0.001 compared in the presence or absence of LLLT or between 
indicated groups.
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group, with platelet counts below 50% of the control (P < 0.01 on day 2; P < 0.05 on day 3; and P < 0.05 on day 4). 
Moreover, bleeding time in ITP+sham group was lengthened to 120 sec from 50 sec in the control group on day 2 
(P < 0.01, Fig. 1b), and LLLT shortened the bleeding time by 50%, leading to a nearly normal level in ITP+LLLT 
group (P < 0.01, Fig. 1b). We then extended our investigation to another ITP model by administering anti-CD41 
antibody twice one on day 0 and the other on day 3 each at 0.5 mg/kg body weight. The mice were treated with 
sham light or LLLT daily from day 0 to day 4 (Fig. 1c). The antibody once again lowered platelet counts signif-
icantly one day after, and platelet counts reached the nadir in 3~4 days with an ~60% decline and remained 
significantly lower up to day 6 in ITP+sham group. The decline of platelet counts was however largely prevented 
by daily LLLT for 5 days, concurrent with normalization of bleeding time in the mice on day 4 in ITP+LLLT 
group (Fig. 1d). The result confirms that LLLT restores not only platelet counts but also platelet function in mice 
receiving anti-CD41 antibody.
LLLT partially reverses antibody-mediated inhibition of MK differentiation. To address the 
mechanism underlying thrombopoietic effect of LLLT, mouse bone marrow nucleated cells were differentiated 
for 72 hr in the presence of an increasing concentration of anti-CD41 antibody in serum-free expansion medium 
supplemented with 100 ng/mL TPO, called MK medium hereafter. Anti-CD41 antibody significantly lowered the 
number of MKs in a dose-dependent manner (Fig. 2a), in agreement with hampering MK differentiation by the 
antibody. The number of MKs was reduced by 65% in the presence of 0.08 μ g/mL anti-CD41 antibody (P < 0.001, 
Fig. 2a), and this antibody concentration was used in subsequent investigation of LLLT efficacy. Exposure of the 
cell culture to a single dose of LLLT (1 x LLLT) at either 1 or 3 J/cm2 at 2 hr after antibody addition exhibited little 
effect on MK differentiation (Fig. 2b), while increasing the energy density to 6 J/cm2 gave rise to only modest 
effects (P < 0.05). On the contrary, three doses of LLLT (3 x LLLT) at 3 J/cm2 administered to the cell culture once 
a day for 3 consecutive days starting 2 hr after antibody addition displayed the most significant effect on MK 
differentiation, increasing the MK number by 110% in the presence compared to the absence of LLLT (P < 0.001, 
Fig. 2b), although similar three doses of LLLT were not effective if laser energy was lower (1 J/cm2) or higher 
(6 J/cm2). This biphasic dose-response of LLLT was also reported previously in LLLT-mediated ATP synthesis 
and recovery of traumatic brain injury20,21. The finding that antibody-mediated inhibition of MK differentiation 
can be significantly reversed only after multiple doses of LLLT may be due to its accumulative effect on a specific 
differentiation stage of MKs, which is supposed to be continuously formed throughout the 3-day differentiation 
culture. The ability of LLLT to partially reverse the antibody-mediated inhibition of MK differentiation may con-
tribute, at least in part, to its mitigation of ITP in vivo (Fig. 1).
LLLT improves proplatelet and platelet formation in the presence of anti-CD41 antibody. 
Apart from partial reversal of antibody-mediated inhibition of MK differentiation, LLLT appeared to favorably 
affect the final stages of platelet generation in the presence of anti-CD41 antibody as well. In a 24 hr differentiation 
Figure 2. LLLT rescues MK differentiation in the presence of anti-CD41 antibody. (a) Bone marrow 
nucleated cells were differentiated in MK medium containing indicated concentrations of anti-CD41 antibody. 
The number of MKs was quantified 72 hr later by flow cytometry. (b) Bone marrow nucleated cells were cultured 
for 2 hr in MK medium containing 0.08 μ g/mL anti-CD41 antibody, after which LLLT at indicated energy 
density was given either once (1 x LLLT) or once a day for 3 consecutive days (3 x LLLT). On day 3, the number 
of MKs was measured by flow cytometry as (c). All data represent mean ± SEM; n = 6, *P < 0.05, **P < 0.01, and 
***P < 0.001 compared in the presence or absence of LLLT or between indicated groups.
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culture of MKs, the cells converted their entire cytoplasm into many long protrusions and branches of proplatelets 
forming a complex network or blossom-like cell, which were readily seen under a phase contrast microscope in 
the absence of anti-CD41 antibody (Fig. 3a, left panel), but the complex networks of proplatelet-forming MKs 
were seldom seen in the presence of the antibody (Fig. 3a, middle panel), corroborating severe hindrance of 
Figure 3. LLLT partially reverses antibody-mediated hindrance of proplatelet and platelet formation. 
Mature MKs were sorted and differentiated in MK medium with or without indicated concentrations of 
anti-CD41 antibody and LLLT was given 2 hr later. (a) Representative images of proplatelet formation at 
24 hr after initial culture. Filled triangles represent one of many protrusions on proplatelet shafts and unfilled 
triangles indicate the nucleus. Scale bar, 50 μ m. The percentages of MKs forming proplatelets were determined 
in the presence of indicated concentrations of anti-CD41 antibody without LLLT (b) or with LLLT (c). (d) The 
number of platelets derived from 1 × 104 MKs was estimated after the cells were differentiated in MK medium 
for 3 days in the presence of indicated concentrations of anti-CD41 antibody. Antibody-mediated inhibition 
of platelet generation was partially reversed by LLLT (e). All data represent mean ± SEM; n = 6, *P < 0.05, 
**P < 0.01, and ***P < 0.001 compared with control groups or in the presence or absence of LLLT.
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proplatelet formation by the antibody. Percentages of proplatelet-forming MKs declined with a rising concen-
tration of anti-CD41 antibody from 0.05 to 6.25 μ g/mL in a dose-dependent manner (Fig. 3b). While anti-CD41 
antibody at 1.25 μ g/mL caused about 55% reduction in the number of proplatelet-forming MKs (P < 0.001, 
Fig. 3c), a single dose of LLLT at 3 J/cm2 given to the cell culture at 2 hr after antibody addition cut the loss by 
half (Fig. 3a, right panel; and P < 0.01, Fig. 3c). Increasing doses or energy density per dose of LLLT did not 
yield better result in this one-day culture (data not shown). A reduced number of proplatelet-forming MKs was 
proportionally correlated with decreased platelet production in a 3-day differentiation culture. Hence, an increas-
ing anti-CD41 antibody from 0.05 to 6.25 μ g/mL significantly diminished platelet production from 6 to 50 fold 
(Fig. 3d), whereas LLLT restored platelet production by 2-fold in the presence of 1.25 μ g/mL anti-CD41 antibody 
(P < 0.01, Fig. 3e), although it was still much lower than antibody-free controls (p < 0.001, Fig. 3e). These results 
hint that anti-CD41 antibody impairs, but LLLT partially restores, generation of proplatelets and platelets in ITP.
LLLT enhances mitochondrial function and biogenesis in antibody-treated MKs. Our recent 
study showed that LLLT bolstered ATP production and mitochondrial biogenesis in MKs18. Whether or not this 
held true in the presence of anti-CD41 antibody remained unknown. To investigate this, MKs were differenti-
ated in MK medium supplemented with 1.25 μ g/mL anti-CD41 antibody. The differentiation cell cultures were 
subject to sham light or a single dose of LLLT at 3 J/cm2 at 2 hr after antibody incubation, followed by measur-
ing cellular ATP levels in 30 min. ATP production declined drastically in antibody-treated MKs in comparison 
with control cells (P < 0.001, Fig. 4a). A similar declining trend was also evidenced in mitochondrial mass, as 
measured by MitoTracker staining, at 24 hr after initial differentiation culture (P < 0.001, Fig. 4b). Both these 
antibody-mediated impairments were partially but significantly prevented by a single dose of LLLT (P < 0.01, 
Fig. 4a,b).
LLLT prevents platelet apoptosis and prolongs its lifespan. In light of a well-documented role for 
mitochondrial activity in the lifespan of platelets22, we next determined whether LLLT could protect platelets 
from apoptosis and prolong their lifespan, an yet another factor contributing to mitigation of ITP by LLLT seen in 
Fig. 1. To this end, platelets were prepared from mouse blood samples, cultured in MK medium, and treated with 
or without anti-CD41 antibody for 2 hr before exposure of the platelets to LLLT. Measurement of the caspase-3/7 
activity in the platelets revealed a 3.6-fold increase in caspase-3/7 activity, on average, in the presence compared 
to the absence of anti-CD41 antibody (P < 0.001, Fig. 5a). The antibody-induced activation of caspase3/7 was pro-
foundly blunted by LLLT when measured 6 hr post-LLLT (P < 0.001, Fig. 5a). This ex vivo observation was sub-
sequently corroborated in vivo in the passive mouse ITP model treated with LLLT daily at 36 J/cm2 as Fig. 1a. As 
shown in Fig. 5b, daily injection of anti-CD41 antibody led to about 5.6-fold increases in the percentage of plate-
lets expressing activated caspase-3 (p < 0.01, Fig. 5b), when platelets were isolated from the mice on day 2 after 
antibody injection and assayed for caspase-3 activation. However, the proportion of apoptotic platelets declined 
to a near normal level by two doses of noninvasive whole body LLLT of the mice (P < 0.01, Fig. 5b). Since platelet 
apoptosis is correlated with platelet lifespan and clearance23, we monitored circulating platelets in these mice after 
injection of a biotinylation agent as previously described24, which is a common assay for monitoring the lifespan 
of platelets in the circulation. In comparison with control mice, the percentage of biotin-labeled platelets was 
decreased precipitously on day 2 and day 3 and remained below a 50% level on day 3 in ITP + sham mice (Fig. 5c). 
Figure 4. LLLT enhances mitochondrial function and biogenesis in antibody-treated MKs. Sorted MKs 
were differentiated in MK medium supplemented with 1.25 μ g/mL anti-CD41 antibody, followed 2 hr later by 
LLLT or sham light treatment. (a) ATP was measured in 1 × 105 MKs at 30 min post-LLLT. (b) Mitochondrial 
mass was determined 24 hr post-LLLT by staining with MitoTracker followed by flow cytometric analysis. All 
data represent mean ± SEM; n = 6, *P < 0.05, **P < 0.01, and ***P < 0.001 compared in the presence or absence 
of antibody or LLLT.
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In contrast, LLLT was able to sustain biotin-labeled platelets at normal levels, increasing biotin-labeled platelets 
to 87% from 60% on day 2 (P < 0.001, Fig. 5c) and to 56% from 40% on day 3 (P < 0.01, Fig. 5c). These results 
suggest that LLLT prevents platelets from apoptosis and prolongs their lifespan in the presence of anti-platelet 
antibody.
Discussion
The current investigation demonstrates the ability of LLLT to alleviate thrombocytopenia in two ITP mouse 
models25, which are different from the one we recently tested18. While both studies consistently show a potential 
of LLLT to be a novel modality to treat thrombocytopenia, the current study is tailored specifically for ITP, espe-
cially how LLLT can correct the adverse effect of anti-platelet antibody on platelet biogenesis and the survival of 
platelets. Anti-CD41 antibody appears to impair multiple discernible differentiation steps of platelet biogenesis, 
including MK differentiation from the progenitors, proplatelet formation, platelet generation, and the survival 
of platelets. Strikingly, LLLT is able to ameliorate all of these defects caused by anti-CD41 antibody at varying 
degrees through enhancing mitochondrial activity and/or biogenesis, resulting in ITP alleviation and restoration 
of tail bleeding time in antibody-treated mice. The study underscores contribution of mitochondrial stress either 
directly or indirectly to the pathology of ITP, which may open novel avenues for ITP management, for instance, 
by using mitochondrion-promoting drugs.
A loss of immune tolerance to self-antigens is believed resulting in development of various autoantibod-
ies against platelets, MKs, and MK progenitors26. These autoantibodies impair MK differentiation and platelet 
Figure 5. LLLT inhibits platelet apoptosis and prolongs its lifespan. (a) Platelets were prepared from blood 
samples of mice and incubated for 2 hr in MK medium containing 1.25 μ g/mL anti-CD41 antibody before 
treated with LLLT. Caspase-3/7 activity in platelets was measured at 6 hr post-LLLT using Caspase-Glo 3/7 
reagents. (b) The passive mouse ITP model was induced and daily LLLT was administered as Fig. 1a. The 
percentage of platelets expressing activated caspase-3 was assessed by FAM-DEVD-FMK fluorescence in 
platelets prepared from mice 2 days after treated with or without two doses of anti-CD41 antibody and LLLT. 
(c) Platelets were biotinylated in vivo, followed by ITP induction and LLLT as Fig. 1a. The percentage of biotin-
labeled platelets in the circulation was determined by flow cytometry before each antibody injection. All data 
represent mean ± SEM; n = 12; ns, no significance; and *P < 0.05, **P < 0.01, ***P < 0.001 compared in the 
presence or absence of LLLT or anti-CD41 antibody.
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generation and destroy platelets, leading to a low platelet count. The impaired megakaryocytopoiesis and platelet 
production in ITP pathogenesis have been demonstrated in several animal models and MK morphologic stud-
ies27,28. In vitro cell culture studies have shown that plasma of ITP patients hinders MK differentiation29–31 and 
in some instances also inhibits proplatelet formation32 because the plasma contains autoantibodies directed at 
platelets. Similarly, we found that anti-CD41 antibody hampered MK differentiation, proplatelet formation, and 
platelet generation in a dose-dependent manner (Fig. 3). The investigation provides additional evidence that 
hindrance of the final stages of MK differentiation by autoantibodies contributes to immunopathological mecha-
nisms of ITP32. Two previous studies showed that anti-platelet autoantibodies isolated from chronic ITP patients 
perturbed MK polyploidy apart from MK maturation30,31. This is apparently not the case in our investigation 
because we did not observe any significant reduction of polyploid MKs when bone marrow cells were differen-
tiated into MKs for 3 days in MK medium supplemented with anti-CD41 antibody (data not shown), probably 
owing to different antibodies involved. It is also possible that the discrepancy results from a shorter differentia-
tion time (3 days) in our study, as opposed to a 15-day liquid MK differentiation system in those two studies30,31. 
Nevertheless, our result is consistent with another study using umbilical cord blood cells cultured for 8 days, 
showing the ploidy distributions of MKs were not significant different in cultures containing either control or ITP 
plasma29. Although adverse effects of anti-CD41 antibody on discernible stages of MK differentiation, proplatelet 
and platelet formation and the survival of platelets are well described, the underlying mechanism remains poorly 
understood.
Our finding that LLLT could significantly sustain MK maturation and proplatelet and platelet generation in the 
presence of anti-CD41 antibody suggests direct or indirect contribution of antibody-induced mitochondrial stress 
to the pathology of ITP, in light of the well-documented benefits of LLLT to mitochondria. LLLT has been shown 
to preserve mitochondrial function and increase ATP synthesis in various cells under stress12,13,33. Moreover, we 
recently demonstrated that LLLT protected mitochondrial function in irradiated MKs, facilitating thrombopoie-
sis after irradiation in mice18. MK maturation and proplatelet formation are highly energy-consuming processes 
and mitochondria are crucial in these differentiation processes as we showed that the yield of platelet production 
was correlated proportionally with the number of mitochondria or the level of ATP production in the cells18. An 
importance of mitochondria in the final stage of platelet biogenesis is also consistent with migration of MKs from 
low-oxygen niches in the bones toward the sinusoidal blood vessels during proplatelet formation and platelet 
release from MKs because a high level of oxygen around the sinusoidal blood vessels warrants higher mito-
chondrial oxidative phosphorylation34. On the contrary, inadequate ATP production in MKs lacking immediate 
early responsive gene X-1 (IEX-1) hindered proplatelet formation18. In accordance with this, anti-CD41 antibody 
severely blunts ATP production and/or mitochondrial biogenesis (Fig. 4), which correlates well with hindrance 
of MK differentiation and platelet biogenesis by the antibody. The observations argue not only for mitochondrial 
stress as one of the etiologies of ITP but also for the mechanism underlying LLLT-mediated alleviation of ITP.
Apart from inhibition of MK differentiation and platelet formation, anti-platelet antibody appears 
to induce apoptosis of platelets, which may be another factor contributing to the immunopathology of 
ITP23,26,35. Anti-platelet autoantibody has been shown to increase mitochondrial inner membrane potential 
(∆ ψ m) depolarization, caspase-3,8,9 activation and phosphatidylserine exposure in platelets23,35, indicating a 
mitochondrion-dependent apoptosis pathway involved. In support of a role for platelet apoptosis in ITP patho-
genesis, caspase-3 activation is greatly elevated in platelets by anti-CD41 antibody, shortening the lifespan of 
circulating platelets. On the contrary, LLLT significantly inhibits platelet apoptosis, and prolongs platelet lifespan, 
a finding that is not reported in our previous study18. The mechanism underlying LLLT-mediated protection 
against apoptosis of platelets is likely associated with the ability of LLLT to protect mitochondrial functions in the 
presence of anti-CD41 antibody.
LLLT has been a therapeutic approach for analgesics, anti-inflammation and wound healing in the clin-
ics for 30 years with a long recorded safety. Although the current study primarily targets thrombocytopenia 
induced by anti-CD41 antibody, LLLT-mediated enhancement of platelet production should be extended to ITP 
caused by other etiologies, such as anti-CD42b antibody or pathogenic T/B cell reactivity29,36, as well as to those 
acquired thrombocytopenia that are not mediated by an immune mechanism including HIV, chemotherapy, and 
irradiation-induced thrombocytopenia18.
Methods
Mice. C57BL/6 mice at 6–8 weeks of age were purchased from Charles River Laboratories. The mice were 
maintained in a 12-hour light/dark cycle. The animal protocol was approved by the subcommittee on Research 
Animal Care of the Massachusetts General Hospital. All animal experiments in this study were performed 
according to the National Institutes of Health guidelines for the Care and Use of Laboratory Animals.
ITP induction. Mice were intraperitoneally injected with anti-CD41 antibody (BD Bioscience) either daily 
at 0.1 mg/kg body weight in PBS or on day 0 and 3 only each at 0.5 mg/kg body weight. Control mice were intra-
peritoneally injected with 400 μ L PBS in parallel. Platelet counts were analyzed on a HemaTrue veterinary hema-
tology analyzer (Heska Corporation) with 50 μ L whole blood collected from the retro-orbital venous plexus into 
EDTA-coated microtainer tubes (BD Bioscience)
Low-level light treatment. LLLT was performed by an array of near infrared LEDs at 830 nm (Photo 
Therapeutics, Inc). For whole body illumination of a mouse, the hair-removed mouse was subject to LED irra-
diation at 4 hr after anti-CD41 antibody injection. The average irradiance of LED was 20 mW/cm2 and the total 
exposure time was 30 minutes to achieve an energy density of 36 J/cm2. For in vitro studies, MK or platelet cul-
tures were exposed to LED at 2 hr after anti-CD41 antibody incubation, with an average irradiance of 20 mW/cm2 
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and different energy densities specified in each experiment. The sham light was administered similarly with a 
small soft white LED light bulb (3 W, A15) from General Electric.
Bleeding time analysis. Tail bleeding time was determined as previously described24. Briefly, the tail was 
transected at 5 mm from the tip while the mouse was strained in a restrainer (Braintree Scientific). The bleed-
ing tail was immersed in a 15-ml test tube containing 37 °C pre-warmed PBS. Then the time to cessation was 
measured.
MK differentiation from bone marrow cells. Bone marrow cells were flushed from femur and tibia of 
the mice by Hanks’ balanced salt solution (HBS, Sigma) supplemented with 100 U/mL penicillin-streptomycin 
(Life Technologies), and filtered through a 100-μ m strainer. After removal of red blood cells using ACK lys-
ing buffer (Quality Biological), the cells were seeded in 6-well plates at a concentration of 1 × 106 cells/mL in 
StemSpan serum-free expansion medium (STEMCELL Technologies) supplemented with 100 ng/ml TPO and 
differentiated for indicated days.
Flow cytometric analysis and cell sorting. To sort MKs, mouse bone marrow cells were incubated with 
fluorescein isothiocyanate (FITC)-conjugated anti-mouse CD41 antibody (Biolegend) for 20 min on ice. Mature 
MKs were sorted using FACSAria (BD Bioscience) based on CD41 expression and forward/side scatterhigh. To 
quantify platelets produced by MKs, platelets were collected from day-3 differentiation cultures and analyzed by 
FACSAria on the basis of CD41 expression and forward/side scatterlow. Mitochondria of MKs were stained with 
200 nM MitoTracker Deep Red FM (Molecular Probes) at 37 °C for 30 min, followed by measuring the mean fluo-
rescence intensity at 660 nm by flow cytometry. To analyze caspase-3 activation, platelets were isolated from mice 
and stained with allophycocyanin (APC)-conjugated anti-CD41 antibody (Biolegend) and FAM-DEVD-FMK 
(Cell Technology) that can enter the cells and irreversibly bind to activated caspase-3 specifically. The proportion 
of platelets with activated caspase-3 was quantified by the histogram at 488 nm according to the manufacturer’s 
instruction. All flow cytometric data were analyzed by FlowJo software (Tree Star).
Proplatelet formation assay. CD41-positive mature MKs were sorted from bone marrow cells by 
FACSAria as described above and seeded in 24-well plates at a concentration of 2000 cells/mL in StemSpan 
serum-free expansion medium supplemented with 100 ng/mL TPO. After differentiation for 24 hr, the number of 
MKs displaying proplatelets relative to the total number of MKs was counted under a phase contrast microscope 
(Zeiss Axio Observer Z1) using a 40x objective at phase II.
Luminescent assay of ATP and caspase-3/7 activity. Mature MKs were sorted from bone marrow cells 
and seeded in 24-well plate at 1 × 105 cells per well in MK medium. At 30 minutes after LLLT, MKs were collected 
for ATP quantification using an ATP detection kit (Promega) according to manufacturer’s instructions. The ATP 
level was normalized to protein concentrations obtained by the Bradford method (BioRad Protein Assay kit). 
To measure caspase activation, platelets were prepared from blood samples of indicated mice, seeded in 96-well 
plate at 2 × 104 platelets per well in MK medium, and incubated with or without anti-CD41 antibody for 2 hr, after 
which 100 μ L of Caspase-Glo 3/7 reagents (Promega) were added in triplicate to each well 6 hr post-LLLT. After 
gently mixing in a plate shaker for 30 seconds and incubation at room temperature for 1 hr, luminescence of each 
sample was measured on a microplate reader (Molecular Devices) per the manufacturer’s instruction.
Platelet preparation. Blood samples were collected from the retro-orbital venous plexus into polypropyl-
ene tubes (Axygen) containing 10% citrate-dextrose solution (Sigma). Platelet rich plasma was obtained by cen-
trifugation of the blood samples at 200 g for 10 minutes. The resultant platelet rich plasma was then incubated 
with 0.1 μ g/mL Prostaglandin E1 (Sigma) in PBS for 10 minutes at room temperature and concentrated by cen-
trifugation at 2250 g for 15 minutes. The concentrated platelets were cultured ex vivo for 2 hr in the presence or 
absence of anti-CD41 antibody before subjecting to LLLT or sham light and measurement of caspase-3/7 activity 
by Caspase-Glo. To measure caspase-3 activation in platelets in vivo, platelets were prepared from mice after 
treated with or without anti-CD41 antibody for 2 days, along with two doses of LLLT or sham light. Caspase-3 
activation was assayed by FAM-DEVD-FMK staining.
Platelet lifespan analysis. Platelet lifespan was monitored by in vivo biotinylation as previously described24. 
In brief, 3 mg EZ-link-N-Hydroxysulfosuccinimide-Biotin (EZ-NHS-Biotin, Pierce) was intravenously injected 
into each mouse. Blood samples were obtained at indicated days and incubated with FITC-anti-CD41 and phyco-
erythrin (PE)-conjugated streptavidin (Biolegend), followed by flow cytometric analysis of biotinylated platelets.
Statistical analysis. Statistical significance was assessed by two-tailed student’s t test for two-group com-
parison or one way analysis of variance (ANOVA) for multiple-group comparison using Graphpad Prism 6.0 
(Graphpad Software). A value of P < 0.05 was considered statistical significance.
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